Sponsored Content: Neal Shore, MD, FACS reviews new data on the TITAN trial of apalutamide in patients with mCSPC.
Neal D. Shore, MD, FACS
Advertisement
Articles by Neal D. Shore, MD, FACS
Neal D. Shore, MD, FACS, discusses the approval of relugolix in advanced prostate cancer.
Neal D. Shore, MD, FACS, discusses the need for further education on molecular testing for metastatic castration-resistant prostate cancer.
Neal D. Shore, MD, FACS, discusses unique challenges in nonmetastatic castration-resistant prostate cancer.
Neal D. Shore, MD, FACS, discusses the cardio-oncology strategies that can be implemented in patients with prostate cancer to reduce the chances of a cardio-related adverse-event.
Neal D. Shore, MD, FACS, discusses the safety profiles of relugolix and leuprolide in advanced prostate cancer.
Neal D. Shore, MD, FACS, discusses immunotherapy targeting prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) in biochemically recurrent prostate cancer.
Neal D. Shore, MD, FACS, discusses the rationale for conducting the phase 3 HERO trial in advanced prostate cancer.
Advertisement
Latest Updated Articles
Dr. Neal Shore on Treatment of Elderly Patients With mCRPCSeptember 14th 2016
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts Third RP1 BLA Resubmission With Nivolumab in Advanced Melanoma
2
Real-World Mogamulizumab Elicits Durable Responses in Pretreated Mycosis Fungoides and Sézary Syndrome
3
From "Not Curable" to "May Be Curable": Joshua Richter, MD, on the New Reality of Multiple Myeloma
4
MAIC Shows OS Benefit With Mogamulizumab vs Vorinostat in Cutaneous T-Cell Lymphoma Subtypes
5